Timmermans M, et al. - Researchers assessed the prognostic impact of the amount of residual disease following interval cytoreductive surgery (ICS) on overall survival by analyzing data from 11 individual studies with 2,178 patients. They systematically searched Medline, Embase and Cochrane to find articles for inclusion in the current review. Using the outcome of ICS per study, they assessed median overall survival (mOS). According to the findings of this systematic review, after neoadjuvant chemotherapy, patients with optimal cytoreductive surgery vs patients with suboptimal cytoreductive surgery had extended survival. The most favorable survival outcomes were seen in patients with no macroscopic residual disease; this was comparable to what was seen following primary cytoreductive surgery.